Conditions: Chemotherapy-Induced Nausea and Vomiting (CINV)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 2322
Healthy volunteers: no

Brief summary:
The purpose of this study is to examine the safety, tolerability, and efficacy of MK0517 to prevent Chemotherapy-Induced Nausea and Vomiting (CINV) associated with Cisplatin chemotherapy.

Detailed description:

Arms:
arm 1: Arm 1: study medication arm 2: Arm 2: Active comparator

Interventions: intervention 1: Comparator: fosaprepitant dimeglumine intervention 2: Comparator: Aprepitant intervention 3: Dexamethasone intervention 4: Dexamethasone intervention 5: Ondansetron
Intervention descriptions: intervention 1: single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1. intervention 2: Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3). intervention 3: Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4. intervention 4: Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4. intervention 5: single IV dose of 32 mg of ondansetron on Day 1.

Protocol document: